fidanacogene elaparvovec
Gene therapyexperimental
Spark Therapeutics, Inc. was a developer of gene therapy treatments, which treat debilitating genetic diseases. It was founded in 2013 and has been a subsidiary of Hoffmann-La Roche since 2020. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jul 15, 2019 (NCT03861273)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Studied for
Mechanism of action
- Coagulation factor IXEXOGENOUS GENE
Coagulation factor IX exogenous gene
Gene therapy, factor IX replacement
- Coagulation factor IXSupplementation
F9 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSpark Therapeutics ↗
- ChEMBLCHEMBL3990034 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03861273 | Phase 3 | Jul 15, 2019 | Pfizer |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 1 | 1 | 1 | 2019 |
1 organizations
Page 1 / 1